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Extracellular alpha-synuclein (ASN) could be involved in the pathomechanism of Parkinson’s
disease (PD) via disturbances of calcium homeostasis, activation of nitric oxide synthase and oxida-
tive/nitrosative stress. In this study we analyzed the role of cyclin-dependent kinase 5 (Cdk5) in the
molecular mechanism(s) of ASN toxicity.
We found that exposure of PC12 cells to ASN increases Cdk5 activity via calpain-dependent p25
formation and by enhancement of Cdk5 phosphorylation at Tyr15. Cdk5 and calpain inhibitors pre-
vented ASN-evoked cell death. Our ﬁndings, indicating the participation of Cdk5 in ASN toxicity, pro-
vide new insight into how extracellular ASN may trigger dopaminergic cell dysfunction in PD.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
a-Synuclein (ASN) is a small 140-amino acid, intrinsically disor-
dered protein that is highly abundant in the brain. Although the
physiological role of ASN is not well understood, there is evidence
suggesting that this protein is involved in synaptic vesicle recy-
cling, neurotransmitter synthesis and release, and synaptic plastic-
ity [9,24]. However, oligomerization/aggregation, deposition, and
dysfunction of ASN are common events in neurodegenerative dis-
orders known as synucleinopathies. ASN was shown to be the main
component of characteristic intraneuronal protein aggregates
called Lewy bodies (LB) and Lewy neurites (LN) in Parkinson’s
disease (PD), dementia with LBs (DLB) and in the LB variant of Alz-
heimer’s disease (AD). Recent studies demonstrated that ASN
aggregation may also occur in the sporadic form of AD with a fre-
quency of ca. 60% [19,26]. A growing body of evidence has empha-
sized the importance of extracellular ASN in neurodegenerative
disorders [13,37]. It was suggested that the spread of ASN pathol-
ogy could contribute to the progression of neurodegeneration and
clinical symptoms in PD [23,17]. Nevertheless, the precise mecha-
nism(s) of secretion as well as the consequences of extracellular
ASN action are still unclear. Our previous data showed that extra-
cellular ASN evokes disturbances of calcium homeostasis, thusleading to activation of cytosolic nitric oxide synthase and to acti-
vation of NO-triggered caspase-dependent apoptosis [1,3,5]. An in-
crease in the cytosolic calcium level activates many detrimental
processes in the cell, including overactivation of cyclin-dependent
kinase 5 (Cdk5). Unlike other cyclin-dependen kinases (CDKs),
Cdk5 is not activated by cyclins and it is not directly involved in
regulation of the cell cycle. Instead, Cdk5 has many other impor-
tant functions, including regulation of the central nervous system’s
development, oxidative stress and apoptosis. The activity of Cdk5 is
triggered by binding with the regulatory proteins p35 and p39.
Additionally, the activity of Cdk5 might be regulated by phosphor-
ylation at Tyrosine 15 and Serine 159. In conditions related to an
increased calcium level, overactivated calpains catalyze the prote-
olytic cleavage of p35 and p39, thus leading to the formation of p25
and p29. Due to higher stability, these truncated forms are more
potent activators of Cdk5 and may evoke prolonged activation
and mislocalization of Cdk5. The consequence of Cdk5 overactiva-
tion is hyperphosphorylation of its targets, which may have detri-
mental consequences. This calcium-related, calpain-dependent
mechanism of Cdk5 activation was demonstrated in several neuro-
degenerative disorders, including brain ischemia, AD and PD.
Moreover, it was shown that inhibition of overactivated Cdk5
may be an effective method for neuroprotection in the experimen-
tal models of neurodegenerative diseases [8,25,33]. Previous stud-
ies demonstrated that overactivation of Cdk5 occurs in the brains
of PD patients [6] and in the animal MPTP toxicity model [34,30].
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similar distribution pattern in LBs, and suggested that Cdk5 may
participate in LB formation. It was also suggested that Cdk5 is a
regulator of Parkin ubiquitin-ligase activity [7]. Our previous
studies demonstrated that the cascade evoked by the non-Ab
component of AD amyloid (NAC) involves activation of Cdk5, how-
ever, the link between ASN toxicity and Cdk5 has never been
conﬁrmed [20]. The aim of the present study was to analyze the
role of Cdk5 in an in vitro cellular model of ASN toxicity. Our re-
sults demonstrated, for the ﬁrst time, that treatment with ASN
evokes activation of calpains leading to p35 cleavage and overacti-
vation of Cdk5. The protective effect of Cdk5 inhibition indicated
the importance of Cdk5 in ASN toxicity.
2. Materials and methods
2.1. Preparation of soluble alpha-synuclein
Alpha-synuclein (ASN, rPeptide, Bogart, GA, USA) or beta-synuc-
lein (BSN, rPeptide, Bogart, GA, USA) was dissolved in phosphate-
buffered saline pH 7.4 at a concentration of 100 lM and
immediately used for experiments [2,5]. Aliquots containing 2 lg
of ASN or BSN protein were analyzed by SDS–PAGE, which was
followed by silver staining.
2.2. Cell culture
Rat pheochromocytoma PC12 cells were cultured in Dulbecco’s
Modiﬁed Eagle’s Medium (DMEM) supplemented with 10%
heat-inactivated fetal bovine serum (FBS), 5% heat-inactivatedFig. 1. The effect of ASN and BSN on PC12 cells. PC12 cells were incubated with 10 lM AS
Proteins were subjected to denaturing SDS–PAGE followed by silver staining. Note the pr
BSN on cell viability determined by MTT assay, as described in the Methods section. (C
described in the Methods section. (D) The effect of ASN and BSN on the cytoplasmic ca
A23187 used as a positive control. Data represent the mean value ± S.E.M. for 3–14 indep
cells using a one-way ANOVA followed by the Newman–Keuls test.horse serum, 2 mM L-glutamine, 50 U/ml penicillin and 50 lg/ml
streptomycin in a 5% CO2 atmosphere at 37 C. Cell treatment
was performed in low-serum (2% FBS) DMEM to stop proliferation.
Calpeptin, an inhibitor of calpains, Roscovitine and BML-259,
inhibitors of Cdk5, were dissolved in DMSO. The ﬁnal concentra-
tion of DMSO in the cell culture medium did not exceed 0.05%.
2.3. Cytotoxicity assays
For an analysis of the effect of ASN and BSN on cell survival and
death, assays discriminating live and dead cells were performed.
Equal numbers of cells were cultured in a 96-well PEI-coated plate,
and after 24 h the mediumwas changed to (2% FBS) DMEM and the
tested compounds were added. After 48 h incubation in the pres-
ence of the tested compounds, MTT assay and trypan blue staining
were performed.
MTT (0.25 mg/ml) was added to the culture medium and the
cells were incubated for 2 h. The medium was removed, the cells
were dissolved in DMSO and absorbance at 595 nm was measured.
Trypan blue solution (0.4% in 0.81% sodium chloride and 0.06%
potassium phosphate dibasic) was added to the culture medium.
The cells were examined immediately under an optical micro-
scope. The number of blue stained cells and the total number of
cells were counted. If cells took up trypan blue, they were consid-
ered non-viable.
2.4. Cytosolic Ca2+ measurements
Measurement of the intracellular Ca2+ concentration was car-
ried out using ﬂuorescent indicator Fluo-4-acetoxymethyl (AM)N or BSN for 48 h. (A) Electrophoretic analysis of the ASN and BSN aggregation form.
esence of monomers and dimers (indicated by the arrows). (B) The effect of ASN and
) The effect of ASN and BSN on cell death determined by trypan blue staining, as
lcium level determined by the Fluo-4 probe, as described in the Methods section.
endent experiments. ⁄, ⁄⁄⁄ P < 0.05 and 0.001, respectively, compared to the control
Fig. 2. The effect of ASN on the level of Cdk5 protein expression and phosphor-
ylation. PC12 cells were incubated with 10 lM ASN for 48 h. The total level of
protein and phosphorylation of Cdk5 was determined using the Western blotting
method. (A) Immunoreactivity of Cdk5, phospho-Cdk5 (Tyr15) and GAPDH, which is
presented as a loading control. C-control, ASN – ASN-treated group. (B) Densito-
metric analysis of Cdk5 immunoreactivity. (C) Densitometric analysis of phospho-
Cdk5 (Tyr15) immunoreactivity. Results were normalized to GAPDH levels. Data
represent the mean value ± S.E.M. for 5–6 independent experiments. ⁄P < 0.05,
compared to the PC12 cells, using a Student’s t-test.
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with 10 lM Fluo-4 AM (Invitrogen) supplemented with 2.5 mM
Probenecid for 60 min at 37 C in a Hanks’ Balanced Salt Solution
with 20 mM Hepes pH 7.4 (HBSS). The cells were washed with
HBSS containing 2.5 mM Probenecid and, to ensure complete AM
ester hydrolysis, kept for 30 min at 37 C in the dark. After a second
wash step, ﬂuorescence was determined with a ﬂuorescence read-
er (FLUOstar Omega; BMG LABTECH, Ortenberg, Germany) at 485/
520 nm. Treatment of cells was performed with the following ﬁnal
concentrations: 10 lM ASN, 10 lM BSN (negative control) and
10 lM A23187 (positive control).
2.5. Determination of apoptosis
Apoptotic body formation by the cells was determined by
microscopic analysis of the cells stained with Hoechst 33342.
The cells were examined under a ﬂuorescence microscope (Olym-
pus BX51, Japan) and photographed with a digital camera (Olym-
pus DP70, Japan). Cells with typical apoptotic nuclear
morphology (nuclear shrinkage, condensation) were identiﬁed as
apoptotic and counted. The results were expressed as an apoptotic
index according to the equation apoptotic index = (apoptotic ra-
tio)/(average apoptotic ratio for control), where apoptotic
ratio = (apoptotic cells)/(all cells).
2.6. Western immunoblotting
The cells were washed two times with ice-cold PBS and lyzed.
Protein levels were determined using the Lowry method, then
the samples were mixed with Laemmli buffer and denatured at
95 C for 5 min. After SDS–PAGE (10%), the proteins were trans-
ferred to a PVDF membrane and used for immunochemical detec-
tion in standard conditions.
2.7. PCR
The cells were washed twice with ice-cold PBS, scraped from
the culture dish and centrifuged brieﬂy (3 min, 1000g). RNA
was isolated from the cell pellet using TRI-reagent according to
the manufacturer’s protocol (Sigma–Aldrich, St. Louis, MO, USA).
Digestion of DNA contamination was performed using DNase I
according to the manufacturer’s protocol (Sigma–Aldrich, St.
Louis, MO, USA). RNA quantity and quality was controlled by
spectrophotometric analysis and gel electrophoresis. Reverse tran-
scription was performed using a High Capacity cDNA Reverse
Transcription Kit according to the manufacturer’s protocol
(Applied Biosystems, Foster City, CA, USA). Quantitative PCR was
performed on an ABI PRISM 7500 apparatus using pre-developed
TaqMan Gene Expression Assays (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s protocol:
Cdk5-Rn00590045_m1; Cdk5r1-Rn02132948_s1; Cdk5r2-
Rn01400841_s1; Actb-4352340E. Actb was used as a reference
gene. The relative levels of mRNA were calculated using the DDCt
method.
2.8. Statistics
Statistical analysis was performed with Graph Pad Prism
version 5.0 (Graph Pad Software, San Diego, CA). Differences
between means were analyzed using the Student’s t-test between
two groups or one-way analysis of variance ANOVA with the
Newman–Keuls post hoc test among multiple groups. Data
are presented as means ± S.E.M. P < 0.05 was considered
signiﬁcant.3. Results
In the present study we investigated the role of Cdk5 in the
molecular mechanism of extracellular ASN toxicity. In order to
characterize and visualize what kind of ASN and BSN species
(monomers, oligomers) were formed directly after solubilization
Fig. 3. The effect of ASN on the p35 protein. PC12 cells were incubated with 10 lMASN for 48 h. The total level of protein was determined using theWestern blotting method.
(A) Immunoreactivity of p35, p25 and GAPDH, which is presented as a loading control. (B) Densitometric analysis of p35 immunoreactivity. (C) Densitometric analysis of p25
immunoreactivity. (D) Calculation of ratio p25/p35 immunoreactivity. All results were normalized to GAPDH levels. Data represent the mean value ± S.E.M. for 6–8
independent experiments. ⁄P < 0.05, compared to the PC12 cells, using a Student’s t-test.
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separated by denaturing SDS–PAGE, which was followed by silver
staining. The results indicated the dominant presence of mono-
mers (ca. 17 kDa) and some fraction of dimers (ca. 34 kDa) in the
ASN preparation. We also detected some very weak bands around
60–65 kDa and some small-sized proteins, which may be the prod-
ucts of protein degradation. Very similar results were obtained for
freshly dissolved BSN (Fig. 1A). Then, in order to study the cyto-
toxic properties of this preparation, the PC12 cells were exposed
to extracellular ASN at 10 lM for 48 h. As shown in Fig. 1B, in these
conditions ASN signiﬁcantly reduced cell viability. Beta-synuclein
(BSN), the protein that is closely related to ASN but does not con-
tain hydrophobic residues from the non-amyloid-beta-component
(NAC) region, was used as a negative control. This protein, charac-
terized by different aggregation behavior than that of the ASN, had
no effect on cell survival at 10 lM. Staining with trypan blue con-
ﬁrmed this observation, thus demonstrating a signiﬁcant increase
in the number of dead cells in the ASN-treated group, but not in
the BSN-treated group (Fig. 1C).
To analyze whether the effect of ASN on PC12 cells may be
dependent on deregulation of calcium homeostasis, we analyzed
the intracellular calcium level by using calcium-sensitive probe
Fluo-4. We found that ASN (10 lM) evoked a rapid enhancement
of Fluo-4 ﬂuorescence, thus indicating an increase in the cytosolic
calcium level (Fig. 1D). The progressive rise of the calcium concen-
tration in the cytosol of ASN-treated cells was observed even up to
6 h. BSN (10 lM) did not affect the calcium level.
Then we analyzed the effect of extracellular ASN on the expres-
sion and protein level of Cdk5 and its co-activators. Quantitative
RT-PCR measurement of the mRNA level for Cdk5, Cdk5r1 (coding
p35) and Cdk5r2 (coding p39) demonstrated no changes in gene
expression for the Cdk5 and Cdk5 regulatory proteins p35 and
p39 (results not shown). Western blot analysis was performed to
analyze both the alterations of the Cdk5 protein level and phos-
phorylation. Extracellular ASN had no effect on the total level ofthe Cdk5 protein, however, it signiﬁcantly increased the level of
phospho-Cdk5 (Tyr15) immunoreactivity, thus indicating that the
activity of Cdk5 should be increased (Fig. 2).
The best known mechanism of detrimental overactivation of
Cdk5 is calcium-induced calpain-dependent proteolytic cleavage
of the p35 protein. Our analysis indicated that both the mRNA
and protein level of p35 were not changed after ASN treatment.
However, ASN signiﬁcantly increased the formation of a truncated
p25 protein. The elevated p25/p35 ratio suggests that ASN may
activate the calpain-dependent cleavage of p35 (Fig. 3).
To conﬁrm the role of calpains and Cdk5 in ASN-evoked cell
death, the effect of speciﬁc inhibitors on cell viability after ASN
treatment was analyzed by MTT assay. As shown in Fig. 4, a toxic
effect of ASN on PC12 cells was efﬁciently prevented by Roscovi-
tine and BML-259, the inhibitors of Cdk5. Also, Calpeptin, an inhib-
itor of calpains, protected the cells against ASN-evoked toxicity.
These inhibitors had no effect on cell viability in control conditions.
Nuclei staining with Hoechst 33342 indicated that activation of
apoptosis may be partially responsible for the reduced viability of
PC12 cells treated with extracellular ASN (Fig. 5). As shown in
Fig. 5, ASN evoked a signiﬁcant increase in the number of cells dis-
playing all characteristic hallmarks of apoptosis (condensation of
chromatin, nuclear fragmentation, etc.). Roscovitine, BML-259
and Calpeptin effectively decreased the number of apoptotic cells
after ASN-treatment, which indicates the important role of cal-
pain-dependent Cdk5 overactivation in the ASN-induced apoptotic
process. Roscovitine, BML-259 and Calpeptin had no effect on the
apoptotic index in the control PC12 cells (data not shown).
4. Discussion
ASN has been implicated in the pathogenesis of PD and related
neurological disorders. As a component of LBs, ASN is rather neu-
tral, but several studies suggested the toxic properties of ASN
[35]. Recent studies have identiﬁed the presence of ASN in the
Fig. 4. The role of Cdk5 in ASN-evoked cell death. PC12 cells were incubated with
10 lM inhibitors in the presence of 10 lM ASN for 48 h. BML-259 and Roscovitine
were used as Cdk5 inhibitors, Calpeptin was used as the calpain inhibitor. Cell
viability and the apoptotic index were determined as described in the Methods
section. Data represent the mean value ± S.E.M. for 14 independent experiments.
⁄⁄⁄P < 0.001, compared to the control cells; #, ##, ### P < 0.05, P < 0.01, P < 0.001,
compared to the ASN-treated cells using a one-way ANOVA followed by the
Newman–Keuls test.
Fig. 5. The role of Cdk5 in ASN-evoked apoptosis. PC12 cells were incubated with
10 lM inhibitors in the presence of 10 lM ASN for 48 h. BML-259 and Roscovitin
were used as Cdk5 inhibitors, Calpeptin was used as the calpain inhibitor. (A) The
apoptotic index was determined as described in the Methods section. Data
represent the mean value ± S.E.M. for 3 independent experiments. ⁄⁄⁄P < 0.001,
compared to the control cells; ##, ###P < 0.01, P < 0.001, compared to the ASN-
treated cells using a one-way ANOVA followed by the Newman–Keuls test. (B)
Representative images are presented. The arrows indicate nuclei with typical
apoptotic features after 48 h of treatment.
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may also occur in the extracellular milieu via an unknown mecha-
nism. Our own data showed that ASN is liberated from synapto-
neurosomes into the extracellular space [4]. Extracellularly acting
ASN was recognized as a potentially toxic agent which may be
responsible for propagation of neurodegenerative processes in
the brain [12,37,29]. Therefore, both ASN release mechanisms as
well as the possible functions of extracellular ASN have been inten-
sively studied.
In the present study we analyzed the contribution of Cdk5 in
detrimental processes activated by extracellular ASN. In this study
we used a preparation of soluble ASN, which mainly consisted of
monomeric forms and a small fraction of dimers. Our previous
studies demonstrated that this preparation of ASN evoked signiﬁ-
cant cell death only at a concentration of 10 lM, inversely to the
10 lM aggregated form of ASN that had no signiﬁcant effect on cell
viability [20]. As an experimental in vitro model we used rat pheo-
chromocytoma (PC12) cells. This cell line is of neuronal origin and
is commonly used as a model for studying neuronal cell function
and differentiation [15,16,28]. PC12 cells synthesize catechola-
mines, dopamine and norepinephrine and express tyrosine
hydroxylase and choline acetyltransferase [28] as well as func-
tional Cdk5 and p35/p39 proteins [11].
Our results indicated that extracellular ASN exerts its toxic ef-
fect partially by activation of Cdk5. Overactivation of this enzyme
has been observed in several neurodegenerative diseases con-
nected with the deregulation of calcium homeostasis, such as AD,
PD or brain ischemia [14,38,34,31]. Our previous data indicated
that extracellular ASN signiﬁcantly affects the intracellular calcium
level [2]. The increase in the cytosolic calcium concentration in-
duces calpain activation, which in turn may evoke the proteolytic
cleavage of p35 and p39, the activators of Cdk5. Enhanced activity
of Cdk5 leads to increased phosphorylation of a broad range ofsubstrates, which has detrimental consequences on the cell. This
mechanism was demonstrated in several models of neurodegener-
ation. Our present data demonstrated, for the ﬁrst time, that extra-
cellular ASN also activated this cascade. The calpain inhibitor,
Calpeptin, efﬁciently prevented ASN-evoked cell death. We
presented that ASN activated the calpain-dependent proteolysis
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we observed an alternative mechanism of Cdk5 activation by en-
hanced phosphorylation of this enzyme at Tyr15 in the ASN-trea-
ted cells. Several kinases (Fyn, c-Abl, TrkB, Eph4, HER2 and
FGFR1) and protein phosphatase 1 are responsible for regulation
of Cdk5 phosphorylation at this site [32,41,27,18]. Therefore, the
exact mechanism responsible for this phenomenon needs further
investigation.
There are several possible mechanisms of Cdk5-dependent cell
death in ASN-treated cells. First, it is known that Cdk5 binds to and
phosphorylates the p53 protein (S15; S83), thus modulating its
transcriptional activity which, in consequence, may lead to
enhancement of expression of the pro-apoptotic BAX protein with
concomitant activation of caspase-3 [22,40]. Our previous data
demonstrated that exogenous ASN induces mitochondrial dysfunc-
tion and caspase-3 activation leading to apoptotic cell death [5,20].
Moreover, the interplay between protein p53 and Cdk5 was re-
cently proposed as a novel mechanism of neurotoxicity induced
by the toxic fragment of ASN, the NAC peptide [21]. Thus the acti-
vation of the Cdk5-p53-caspase-3 pathway by exogenous ASN
seems to be the most probable mechanism of cell death evoked
by this protein.
It has recently been suggested that the N-terminal product of
the calpain-catalyzed cleavage of p35, p10, may also exert neuro-
toxic properties [10]. However, as was demonstrated in the present
study, the inhibitors of Cdk5 effectively prevented ASN-evoked
apoptosis, thus indicating that p10-related toxicity has a negligible
signiﬁcance on the molecular mechanism of extracellular ASN
action.
It was also proposed that Cdk5, by inducing phosphorylation of
endophilin B1, plays an important role in the regulation of autoph-
agy in neurons [39]. It is likely that other types of cell death evoked
by ASN, including autophagy, may be activated by Cdk5. In agree-
ment with this hypothesis, our previous study demonstrated the
presence of the characteristic hallmarks of autophagy in PC12 cells
treated with the NAC peptide [21].
Our results demonstrated, for the ﬁrst time, that extracellular
ASN triggers deregulation of the Cdk5 function via calcium-depen-
dent activation of calpains, which leads to p35 cleavage and, as a
result, to the formation of the p25 protein. This then evokes a sig-
niﬁcant enhancement of Cdk5 activity. In addition, the increase in
ASN-evoked phosphorylation on Tyr15 may be partially responsi-
ble for Cdk5 overactivation. The protective effect of Cdk5 inhibition
conﬁrmed the importance of this enzyme in the molecular mecha-
nisms of ASN toxicity, however, the complete characterization of
speciﬁc Cdk5 targets responsible for cell death initiation after
ASN treatment needs further investigations.
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